Press Releases

Date Title and Summary
Toggle Summary Accuray Generates $108.9 Million in Second Quarter Revenues
Record Revenues Achieved as Commercial Execution Continues; Management Reaffirms Fiscal 2016 Guidance SUNNYVALE, Calif. , Jan. 28, 2016 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today financial results for the second fiscal quarter and six months ended December 31, 2015 .
Toggle Summary Accuray Generates $105.3 Million in Third Quarter Revenues
Achieves 8% year-over-year revenue growth; Generates $5.4 million of operating income SUNNYVALE, Calif. , April 26, 2016 /PRNewswire/ --  Accuray Incorporated (NASDAQ: ARAY) announced today financial results for the third fiscal quarter and nine months ended March 31, 2016 .
Toggle Summary Accuray Generated $55.6 Million in First Quarter Gross Orders; Revenue Increased 5 Percent Year over Year
SUNNYVALE, Calif. , Oct. 24, 2017 /PRNewswire/ --  Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the first fiscal quarter ended September 30, 2017 . First Quarter Highlights Gross orders increased 11 percent to $55.6 million , net orders were $51.0 million .
Toggle Summary Accuray Fiscal Second Quarter Revenue Exceeds $100 Million and Increases 15 Percent Year-over-Year; Gross Orders of $77.9 Million; Backlog Up 10 Percent
SUNNYVALE, Calif. , Jan. 23, 2018 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the second fiscal quarter ended December 31, 2017 . Fiscal Second Quarter Highlights Revenue increased 15 percent year-over-year to $100.3 million driven by product revenue
Toggle Summary Accuray Extends Industry-Leading Customer Service Program to TomoTherapy Systems
New TomoTherapy Emerald Service Program Combines Best in Class Product Service Offerings with Guaranteed Uptime for Unparalleled Reliability and Customer Satisfaction SUNNYVALE, Calif., Sept. 6, 2011 /PRNewswire via COMTEX/ -- Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology
Toggle Summary Accuray Expands Treatment Options for Patients in Finland
CyberKnife Radiosurgery Provides Patients an Effective, Non-Invasive and Convenient Treatment Option SUNNYVALE, Calif., April 2, 2012 – Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, announced today that Kuopio University Hospital in Kuopio, Finland has begun treating
Toggle Summary Accuray Expands Global Training Center Network With Opening of New Facility in Genolier, Switzerland
  The new center is the most recent addition to the company's existing training hubs in Madison, Wisconsin ( U.S. ), Tokyo, Japan and Tianjin, China     Each facility offers a range of educational opportunities designed to advance patient care using the Accuray CyberKnife ® and Radixact ® Systems
Toggle Summary Accuray Expands Direct Sales Presence Into India
Company Dedicates Local Resources to Expand Access to CyberKnife Radiosurgery for Country's Growing Aging Population SUNNYVALE, Calif., March 24, 2010 /PRNewswire via COMTEX/ -- Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, announced today that the company has
Toggle Summary Accuray Expands CyberKnife® System Versatility with Integration of RaySearch's RayStation Treatment Planning System
Treatment Planning for the CyberKnife System and Other Radiation Therapy Devices Can Now be Performed Using the Same Software Solution SUNNYVALE, Calif. , June 16, 2021 /PRNewswire/ --  Accuray Incorporated (NASDAQ: ARAY) announced today the launch of RayStation* treatment planning support for the
Toggle Summary Accuray Expands Commercialization of ClearRT™ Helical Fan-Beam kVCT Imaging for the Radixact® System with CE Mark Certification
Expands Global Access to Exceptional Quality Diagnostic-like CT Images for Medical Care Teams Using the Radixact System SUNNYVALE, Calif. , June 10, 2021 /PRNewswire/ --  Accuray Incorporated (NASDAQ: ARAY) announced today the company has received CE Mark certification for its ClearRT ™ helical

*The quarterly and year-end results reported herein were subsequently revised for adjustments that were immaterial, individually and in the aggregate. The revised quarterly and year-end results are included in our Annual Report on Form 10-K, filed with the Securities and Exchange Commission (the "SEC") on August 25, 2020, and are accessible on our website at https://investors.accuray.com/financial-information/sec-filings and on the SEC's website at www.sec.gov.